• Angiotensin 1/2 (5-7): Assay Interpretation Guide

  2026-08-19

  Angiotensin 1/2 (5-7) is a compact H2N-Ile-His-Pro-OH peptide for studying fragment-specific renin-angiotensin biology. This guide explains how to interpret cardiovascular and spike-receptor binding data without confusing biochemical activity with clinical or infectious-disease causation.

• MLN2238: Designing Causal Proteostasis Assays

  2026-08-19

  MLN2238 is a potent proteasome β5 subunit inhibitor for dissecting proteotoxic stress, apoptosis, and adaptive signaling. This guide translates ROS–JNK–CREB findings into more informative assay designs for oncology and proteostasis research.

• Dextromethorphan hydrobromide Research Workflows

  2026-08-18

  Build reproducible excitotoxicity, calcium-signaling, and ischemia workflows with a research-grade NMDA receptor antagonist. This guide pairs practical handling advice with orthogonal assay design, helping distinguish receptor-mediated neuroprotection from nonspecific ion-channel or vehicle effects.

• Minoxidil Sulphate: From Probe to Assay Logic

  2026-08-18

  Minoxidil sulphate is more than a potassium-channel research reagent: it can help separate molecular vasodilation from organ-level vascular dysfunction. This evidence-led guide connects renal perfusion experiments with hair follicle and vascular biology research while defining practical limits for interpretation.

• CUDC-907 Protocol and QC Guide

  2026-08-17

  CUDC-907 is a dual PI3K and HDAC inhibitor for controlled in vitro studies of PI3K/AKT signaling, histone acetylation, cell-cycle progression, and apoptosis. This guide uses product-dossier information and workflow recommendations rather than directly matched paper evidence; the compound is for research use only and not for diagnostic, therapeutic, or clinical applications.

• Perphenazine Workflows for D2 Receptor Research

  2026-08-17

  Perphenazine is a dopamine D2 receptor antagonist that connects receptor pharmacology with mitochondrial toxicity and host-directed antibacterial assays. This practical guide covers compound preparation, ROS and autophagy measurements, macrophage workflows, controls, and troubleshooting for reproducible research.

• Aztreonam in Gram-Negative Research Workflows

  2026-08-16

  Aztreonam offers a defined monocyclic β-lactam framework for Gram-negative susceptibility testing, resistance analysis, and mechanistic cell studies. This workflow-focused guide connects antimicrobial assays with bone marrow and hepatic microsome models while emphasizing solvent control, storage, and interpretation limits.

• Oxaliplatin: From DNA Damage to Translational Strategy

  2026-08-15

  Oxaliplatin is more than a cytotoxicity benchmark: it is a mechanistic probe for studying DNA damage, apoptosis, metastatic heterogeneity, and treatment resistance. This translational guide connects its DNA adduct biology with patient-derived models and strategic experimental design.

• 2,7-Dichlorodihydrofluorescein diacetate Guide

  2026-08-14

  2,7-Dichlorodihydrofluorescein diacetate, also called DCFH-DA, is a cell-permeable fluorogenic reagent for relative intracellular oxidant measurements. Its fluorescence supports microscopy, flow cytometry, and plate assays, but the signal is not specific for one ROS or equivalent to direct DNA-break measurement.

• PP 1: Src Family Kinase Assay Workflows

  2026-08-14

  Turn PP 1 into a practical pathway-dissection tool for Lck, Fyn, Lyn, and RET-driven signaling. This guide combines assay design, concentration planning, orthogonal validation, and troubleshooting for cancer and immunology workflows.

• AZD0156: Reading ATM Inhibition in Cancer

  2026-08-13

  AZD0156 is a selective ATM kinase inhibitor for dissecting DNA damage signaling, repair, and metabolic adaptation. This article translates evidence from high-grade serous ovarian cancer research into a phenotype-centered assay strategy for cancer therapy research.

• Bsa I (RNase-free): Workflow Guide

  2026-08-13

  Bsa I (RNase-free) provides sequence-specific DNA cleavage for cloning and other molecular biology research workflows where RNA integrity must also be protected. It is intended for research use only, not diagnostic or medical applications, and should be used with validated reaction conditions and appropriate RNase-control practices.

• Intravesical p21 mRNA-LNP Therapy in Bladder Cancer

  2026-08-12

  The reference study developed a nonviral tumor suppressor replacement strategy in which chemically modified CDKN1A/p21 mRNA was packaged in lipid nanoparticles for intravesical delivery. Across molecular, cellular, biodistribution, and orthotopic mouse experiments, the approach restored nuclear p21 expression, inhibited bladder tumor growth, and limited systemic exposure, while remaining subject to important preclinical and formulation-specific limitations.

• Masitinib (AB1010): KIT/PDGFR Workflow Guide

  2026-08-12

  Masitinib (AB1010), SKU A2942, is a DMSO-compatible research inhibitor for examining KIT, PDGFRα, and PDGFRβ signaling in cancer, mast cell, and inflammatory models. It is appropriate for targeted in vitro workflows but should not be used where aqueous or ethanol solubility, broad-spectrum kinase inhibition, or clinical treatment guidance is required.

• Phenothiazines Boost Macrophage Antibacterial Activity

  2026-08-11

  The 2025 Frontiers in Immunology study shows that phenothiazines, including perphenazine, strengthen macrophage control of intracellular bacteria by increasing reactive oxygen species, lysosomal activity, and autophagy. Inhibitor and scavenger experiments support a host-directed mechanism, while an in vivo Salmonella Typhimurium model indicates reduced tissue injury and inflammation.

765 records 7/51 page Previous Next First page 上5页 678910 下5页 Last page